GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Debt-to-Revenue

Medigen Biotechnology (ROCO:3176) Debt-to-Revenue : 0.59 (As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Medigen Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was NT$341 Mil. Medigen Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was NT$687 Mil. Medigen Biotechnology's annualized Revenue for the quarter that ended in Sep. 2024 was NT$1,747 Mil. Medigen Biotechnology's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.59.


Medigen Biotechnology Debt-to-Revenue Historical Data

The historical data trend for Medigen Biotechnology's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Debt-to-Revenue Chart

Medigen Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.98 1.99 0.26 2.66 2.52

Medigen Biotechnology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.71 1.96 2.89 0.74 0.59

Competitive Comparison of Medigen Biotechnology's Debt-to-Revenue

For the Biotechnology subindustry, Medigen Biotechnology's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Biotechnology's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Medigen Biotechnology's Debt-to-Revenue falls into.



Medigen Biotechnology Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Medigen Biotechnology's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2195.03 + 716.632) / 1157.72
=2.51

Medigen Biotechnology's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(340.64 + 687.378) / 1746.548
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Medigen Biotechnology Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is a biopharmaceutical company engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The company has four segments: Nucleic acid department: segment, which derives maximum revenue, is responsible for services of testing reagents, instruments and inspection on behalf of others; New drug and vaccine research and development segment: responsible for the development and relevant services of new drugs and vaccine; Cytotherapy department: responsible for research and development and relevant services of cytotherapy; and Generic drug, aesthetic medicine product and dietary supplement segment is responsible for production and sales and relevant services of western medicine, aesthetic medicine product and dietary supplement.

Medigen Biotechnology Headlines

No Headlines